Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

NCT06364956 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: Tislelizumab combined with two predefined dose groups of palbociclib
DRUG: RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial.

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University